MedTrace Logo

Eltrombopag for Treatment of Fanconi Anemia

NCT06045052 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2023-09-21

No results posted yet for this study

Summary

An open-label, phase II study to assess the efficacy and safety of eltrombopag for the treatment of children and adolescents with Fanconi anemia.

Conditions

  • Fanconi Anemia

Interventions

DRUG

Eltrombopag

Eltrombopag tablets by mouth once daily for 24 weeks (6 months) with the dose depending on race, age and weight.

Sponsors & Collaborators

  • Julian Sevilla

    lead OTHER

Principal Investigators

  • Julián Sevilla Navarro, MD, PhD · Hospital Infantil Universitario Niño Jesús (HIUNJ)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
4 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-02
Primary Completion
2023-06-19
Completion
2023-08-29

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06045052 on ClinicalTrials.gov